Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II study of nivolumab in advanced melanoma (ONO-4538-08)
jRCT2080222482Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in melanoma, sponsored by Ono Pharmaceutical. Started May 2014; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2080222482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222482.